 |
市场调查报告书
商品编码
1609382
人源类器官的全球市场：按产品、按来源、按类型、按培养方法、按疾病领域、按应用、按最终用户、按地区 - 预测到 2029 年Human Organoids Market by Product (Liver, Kidney, Pancreatic Models (2D, 3D)), Disease Area (Oncology, GI, Neurological Disorders), Application (Drug Toxicity, Personalized Medicine), End User (Pharma & Biotech Companies, CROs) - Global Forecast to 2029 |
||||||
价格
人源类器官市场规模预计将从 2024 年的 11.9 亿美元增加到 2029 年的 23.3 亿美元，整个预测期内的复合年增长率为 14.4%。
| 调查范围 | |
|---|---|
| 调查年份 | 2022-2029 |
| 基准年 | 2023年 |
| 预测期 | 2024-2029 |
| 考虑单位 | 金额（美元） |
| 按细分市场 | 按产品、原产地、类型、培养方法、疾病领域、应用、最终用户、地区 |
| 目标区域 | 北美、欧洲、亚太地区、拉丁美洲、中东/非洲、海湾合作委员会国家 |
增加对人源类器官研究的资助将透过显着提高研究能力和扩大应用范围来直接推动类器官市场的成长。这笔资金将鼓励科学家研究癌症、神经退化性疾病和药物开发等多个领域的类器官，并将吸引製药和生技公司。随着类器官技术变得更加商业化并且建立了明确的法律规范，进入市场可能会变得更加容易。这正在推动全球人源类器官市场的成长。对人类类器官日益增长的兴趣提供了巨大的市场潜力，但熟练劳动力供不应求。随着对创新类器官技术的需求增加，缺乏开发和使用这些复杂模型的合格人员对持续的研发和商业化工作提出了挑战。
人源类器官市场按应用细分为发育生物学、药物毒性和功效测试、疾病病理学、个人化医疗、再生医学和其他应用。人源类器官为研究独特的人类发育生物学和导致疾病的过程提供了一种本质上更道德和有效的替代方案。因此，它的应用正在取得进展，特别是在专门从事发育生物学的学术和研究中心。
按最终用户划分，人源类器官市场分为製药和生物技术公司、CRO、学术和研究机构以及其他最终用户。由于使用类器官进行药物发现、疾病建模和个人化医疗的积极研发活动，製药和生物技术公司领域预计将以人源类器官市场中最高的复合年增长率成长。这些公司利用类器官开发新药、测试药物功效和毒性，并在细胞层面深入了解复杂疾病。
该报告调查了全球人源类器官市场，并按产品、来源、类型、培养方法、疾病领域、应用、最终用户、地区以及进入市场的公司概况等提供了趋势资讯。
目录
第一章简介
第二章调查方法
第三章执行摘要
第 4 章重要考察
第五章市场概况
- 介绍
- 市场动态
- 价格分析
- 专利分析
- 价值链分析
- 供应链分析
- 贸易分析
- 生态系分析
- 波特五力分析
- 主要相关人员和采购标准
- 监管状况
- 技术分析
- 2024-2025年重大会议和活动
- 影响客户业务的趋势/干扰
- 投资金筹措场景
- 案例研究分析
- 人工智慧对人源类器官市场的影响
第六章 人源类器官市场（依产品）
- 介绍
- 肝臟模型
- 肾臟模型
- 胰臟模型
- 大肠模型
- 心臟模型
- 肺模型
- 其他产品
第七章 人源类器官市场（依来源）
- 介绍
- 成体干细胞
- 诱导性多功能细胞
- 胚胎干细胞
- 其他的
第八章 人源类器官市场（依类型）
- 介绍
- 即用型产品
- 客製化产品
第九章 人源类器官市场（培养法）
- 介绍
- 基质胶基质培养
- 气液界面培养
- 悬浮培养法
- 3D生物列印文化
- 其他的
第10章 人源类器官市场（依疾病领域）
- 介绍
- 瘤
- 肝臟疾病
- 胃肠道疾病
- 心血管疾病
- 感染疾病
- 神经系统疾病
- 其他的
第十一章 人源类器官市场（依应用分类）
- 介绍
- 发育生物学
- 药物毒性及药效测试
- 疾病病理学
- 个人化医疗
- 再生医学
- 其他的
第十二章 人源类器官市场（依最终使用者）
- 介绍
- 製药和生物技术公司
- CRO
- 学术研究所
- 其他的
第十三章 人源类器官市场（按地区）
- 介绍
- 北美洲
- 北美宏观经济前景
- 美国
- 加拿大
- 欧洲
- 欧洲宏观经济展望
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 其他的
- 亚太地区
- 亚太宏观经济展望
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 其他的
- 拉丁美洲
- 拉丁美洲宏观经济展望
- 巴西
- 墨西哥
- 其他的
- 中东/非洲
- 对提高生活品质日益增长的兴趣推动了市场
- 中东和非洲宏观经济前景
- 海湾合作委员会国家
- 日益关注先进医疗基础设施拓展市场
- 海湾合作委员会国家的宏观经济前景
第14章竞争格局
- 介绍
- 主要参与企业的策略/优势
- 2021-2023 年收益分析
- 2023 年市场占有率分析
- 企业评估矩阵：主要参与企业，2023
- 企业评估矩阵：Start-Ups/小型企业，2023 年
- 企业价值评估及财务指标
- 品牌/产品比较分析
- 竞争场景
第十五章 公司简介
- 主要参与企业
- THERMO FISHER SCIENTIFIC INC.
- CORNING INCORPORATED
- MERCK KGAA
- BIOIVT
- HUB ORGANOIDS BV
- BICO
- BECYTES BIOTECHNOLOGIES
- INSPHERO
- GBA GROUP
- KIRKSTALL LTD.
- MIMETAS BV
- NEUROMICS
- PRIMACYT CELL CULTURE TECHNOLOGY GMBH
- STEMCELL TECHNOLOGIES
- 其他公司
- ACROBIOSYSTEMS
- BIOPREDIC INTERNATIONAL
- CN BIO INNOVATIONS LTD.
- CYPRIO
- EMULATE, INC.
- KERAFAST, INC.
- PANDORUM TECHNOLOGIES PVT. LTD.
- CYFUSE BIOMEDICAL KK
- NEYROBLASTGX LLC
- 3DNAMICS INC.
- DEFINIGEN LIMITED
第十六章附录
Product Code: BT 6218
The value of the human organoids market will increase from an estimated USD 1.19 billion in 2024 to USD 2.33 billion in 2029, at a CAGR of 14.4% through the forecast period.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | By Product, Source, type, Culture Method, Disease Area, Application, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries |
Advancement in funding for research in human organoids directly promotes the growth of the market for organoids with significant improvement in research capabilities and increases the scope of applications. Financial support brings scientists to explore organoids in various fields, such as cancer, neurodegenerative diseases, and drug development, which attracts pharmaceutical and biotech companies. A more commercialized version of the organoid technologies along with a clear regulatory framework will even further ease access to the market. This, in turn, is fuelling the growth of the global human organoids market. Although the growing interest in human organoids provides a major market potential, there is a dearth of skilled labor. With such increasing demand in innovative organoid technology, the shortage of qualified personnel who are able to develop and use such complex models has become a challenge to the continued research and commercialization effort.
"Developmental biology segment is expected to have the fastest growth rate in the human organoids market, by application, during the forecast period."
The human organoids market is segmented into developmental biology, drug toxicity & efficacy testing, disease pathology, personalized medicine, regenerative medicine, and other applications, based on application. Human organoids represent an essentially much more ethically compliant and efficient alternative to studying human-specific developmental biology and the processes leading to disease. It is therefore increasingly being applied, especially in academic and research centers specializing in developmental biology.
"Pharmaceutical & biotechnology companies segment accounted for the highest growth rate in the human organoids market, by end user, during the forecast period."
Based on end user, the human organoids market is bifurcated into into pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and other end users. The pharmaceutical and biotechnology companies segment is expected to grow at the highest CAGR in the market of human organoids mainly due to their intense research and development activities, where they use organoids in drug discovery, disease modeling, and personalized medicine. These companies employ organoids in developing new drugs and testing them for the efficacy and toxicity of the drug, besides gaining insights into the complexities of a diseaseat a cellular level.
"Asia Pacific: The fastest-growing region in human organoids market."
The worldwide market for human organoids is categorized into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. Notably, the Asia-Pacific region marks the highest CAGR in the human organoids market, due to increasing investments into healthcare infrastructure and research that advance the capabilities of medical facilities. In addition to this, the number of rapidly aging patients strongly demands effective treatments for diseases related to age. Consequently, human organoids act as great models for the study of such conditions. The growing medical tourism activities in the APAC region also happen to be of great influence for the market, given the rapid increase of patients seeking advanced treatments and high-class healthcare services. These factors, collectively, have put the APAC region on a growth trajectory for human organoids markets.
The break-up of the profile of primary participants in the human organoids market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%
The key players in this market are Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), BioIVT (US), HUB Organoids BV (Netherlands), BICO (Sweden), BeCytes Biotechnologies SL (Spain), InSphero (Switzerland), GBA Group (Germany), Kirkstall Ltd. (UK), MIMETAS BV (Netherlands), Neuromics (US), PRIMACYT Cell Culture Technology GmbH (Germany), STEMCELL Technologies (Canada), ACROBiosystems (China), Biopredic International (France), CN Bio Innovations Ltd. (UK), CYPRIO (France), Emulate, Inc. (US), Kerafast, Inc. (US), Pandorum Technologies Pvt. Ltd (India), CYFUSE BIOMEDICAL K.K. (Japan), NeyroblastGX LLC (US), 3Dnamics Inc. (US), and DefiniGEN Limited (UK).
Research Coverage:
This research report categorizes the human organoids market by product (Liver models, kidney models, pancreatic models, colorectal models, heart models, lung models, other products), by source (adult stem cells, induced pluripotent stem cells, embryonic stem cells, other sources), by type (ready-to-use products, customizable products), by culture method (air-liquid interface culture, suspension culture, matrigel matrix culture, 3d bioprinting culture, and other culture methods), by disease area (oncology, liver diseases, gastrointestinal diseases, cardiovascular diseases, infectious diseases, neurological disorders, and other disease areas), by apllication (developmental biology, drug toxicity & efficacy testing, disease pathology, personalized medicine, regenerative medicine, and other applications), by end user (pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the human organoids market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the human organoids market. Competitive analysis of upcoming startups in the human organoids market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall human organoids market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing focus on developing alternatives to animal testing, rising R&D funding and venture capital investments, increasing research on organoids, increasing prevalence of non-alcoholic fatty liver disease , and need for early detection of drug toxicity to minimize financial losses caused by late-stage drug failure), opportunities (Increasing focus on drug discovery activities, rising demand for organ transplantation, and growth opportunities in emerging economies), restraints (Issues related to incorporating organoids into existing workflows), and challenges (Dearth of skilled professionals) influencing the growth of the human organoids market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the human organoids market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the human organoids market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the human organoids market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), BioIVT (US), and HUB Organoids BV (Netherlands).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.2 RESEARCH APPROACH
- 2.2.1 SECONDARY DATA
- 2.2.1.1 Key data from secondary sources
- 2.2.2 PRIMARY DATA
- 2.2.2.1 Primary sources
- 2.2.2.2 Key data from primary sources
- 2.2.2.3 Key industry insights
- 2.2.2.4 Breakdown of primary interviews
- 2.2.1 SECONDARY DATA
- 2.3 MARKET SIZE ESTIMATION
- 2.3.1 BOTTOM-UP APPROACH
- 2.3.1.1 Approach 1: Company revenue estimation approach
- 2.3.1.2 Approach 2: Presentations of companies and primary interviews
- 2.3.1.3 Growth forecasts
- 2.3.1.4 CAGR projections
- 2.3.2 TOP-DOWN APPROACH
- 2.3.1 BOTTOM-UP APPROACH
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.5 MARKET SHARE
- 2.6 ASSUMPTIONS & LIMITATIONS
- 2.6.1 STUDY ASSUMPTIONS
- 2.6.2 GROWTH RATE ASSUMPTIONS
- 2.6.3 LIMITATIONS
- 2.7 RISK ASSESSMENT
- 2.7.1 RISK ASSESSMENT: HUMAN ORGANOIDS MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 HUMAN ORGANOIDS MARKET OVERVIEW
- 4.2 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2024 VS. 2029
- 4.3 HUMAN ORGANOIDS MARKET, BY SOURCE, 2024 VS. 2029
- 4.4 HUMAN ORGANOIDS MARKET, BY TYPE, 2024 VS. 2029
- 4.5 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2024 VS. 2029
- 4.6 HUMAN ORGANOIDS MARKET, BY END USER, 2024 VS. 2029
- 4.7 HUMAN ORGANOIDS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing focus on developing alternatives to animal testing
- 5.2.1.2 Rising R&D funding and venture capital investments
- 5.2.1.3 Increasing research on organoids
- 5.2.1.4 Increasing prevalence of non-alcoholic fatty liver disease
- 5.2.1.5 Need for early detection of drug toxicity to minimize financial losses caused by late-stage drug failure
- 5.2.2 RESTRAINTS
- 5.2.2.1 Issues related to incorporating organoids into existing workflows
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Increasing focus on drug discovery activities
- 5.2.3.2 Rising demand for organ transplantation
- 5.2.3.3 Growth opportunities in emerging economies
- 5.2.4 CHALLENGES
- 5.2.4.1 Dearth of skilled professionals
- 5.2.1 DRIVERS
- 5.3 PRICING ANALYSIS
- 5.3.1 AVERAGE SELLING PRICE, BY PRODUCT
- 5.3.2 AVERAGE SELLING PRICE, BY REGION
- 5.4 PATENT ANALYSIS
- 5.4.1 LIST OF MAJOR PATENTS
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 SUPPLY CHAIN ANALYSIS
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT DATA (HS CODE 3002)
- 5.7.2 EXPORT DATA (HS CODE 3002)
- 5.8 ECOSYSTEM ANALYSIS
- 5.8.1 ROLE IN ECOSYSTEM
- 5.9 PORTER'S FIVE FORCES ANALYSIS
- 5.9.1 THREAT OF NEW ENTRANTS
- 5.9.2 THREAT OF SUBSTITUTES
- 5.9.3 BARGAINING POWER OF BUYERS
- 5.9.4 BARGAINING POWER OF SUPPLIERS
- 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.10.2 KEY BUYING CRITERIA
- 5.11 REGULATORY LANDSCAPE
- 5.11.1 KEY REGULATIONS
- 5.11.1.1 North America
- 5.11.1.1.1 US
- 5.11.1.1.2 Canada
- 5.11.1.2 Europe
- 5.11.1.3 Asia Pacific
- 5.11.1.3.1 China
- 5.11.1.3.2 Japan
- 5.11.1.3.3 India
- 5.11.1.4 Latin America
- 5.11.1.4.1 Brazil
- 5.11.1.4.2 Mexico
- 5.11.1.5 Middle East & Africa
- 5.11.1.1 North America
- 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.11.2.1 North America
- 5.11.2.2 Europe
- 5.11.2.3 Asia Pacific
- 5.11.2.4 Latin America
- 5.11.2.5 Rest of the world
- 5.11.1 KEY REGULATIONS
- 5.12 TECHNOLOGY ANALYSIS
- 5.12.1 KEY TECHNOLOGIES
- 5.12.1.1 Stem Cell Technology
- 5.12.2 COMPLEMENTARY TECHNOLOGIES
- 5.12.2.1 3D Bioprinting
- 5.12.3 ADJACENT TECHNOLOGIES
- 5.12.3.1 Organ-on-a-Chip
- 5.12.1 KEY TECHNOLOGIES
- 5.13 KEY CONFERENCES AND EVENTS IN 2024-2025
- 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
- 5.15 INVESTMENT AND FUNDING SCENARIO
- 5.16 CASE STUDY ANALYSIS
- 5.16.1 CASE STUDY 1: EVALUATION OF PATIENT-DERIVED ORGANOIDS FOR DRUG SENSITIVITY TESTING IN METASTATIC COLORECTAL CANCER WITH LIMITED TREATMENT OPTIONS
- 5.16.2 CASE STUDY 2: DEVELOPING STABLE ORGANOID MODELS FROM GASTRIC CANCER TISSUES FOR PERSONALIZED MEDICINE AND DRUG SCREENING
- 5.16.3 CASE STUDY 3: OPTIMAL CULTIVATION PERIODS FOR BLADDER CANCER ORGANOIDS BASED ON TRANSCRIPTOMIC PLASTICITY
- 5.17 IMPACT OF AI ON HUMAN ORGANOIDS MARKET
- 5.17.1 KEY USE CASES
6 HUMAN ORGANOIDS MARKET, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 LIVER MODELS
- 6.2.1 2D LIVER MODELS
- 6.2.1.1 Fresh hepatocytes
- 6.2.1.1.1 Increased drug metabolism studies to drive market
- 6.2.1.2 Cryopreserved hepatocytes
- 6.2.1.2.1 High quality and response to support market growth
- 6.2.1.3 Other 2D liver models
- 6.2.1.1 Fresh hepatocytes
- 6.2.2 3D LIVER MODELS
- 6.2.2.1 Liver organoids
- 6.2.2.1.1 Support for determining pharmacology and hepatic toxicity of drugs to treat NAFLD
- 6.2.2.2 3D bioprinted liver models
- 6.2.2.2.1 Increased use in drug discovery to propel market growth
- 6.2.2.3 Liver spheroids
- 6.2.2.3.1 Need for better approaches in drug discovery to promote adoption of spheroids
- 6.2.2.4 Liver-on-a-chip
- 6.2.2.4.1 Stricter regulations on animal testing to promote adoption of in vitro systems like liver-on-a-chip
- 6.2.2.5 Other 3D liver models
- 6.2.2.1 Liver organoids
- 6.2.1 2D LIVER MODELS
- 6.3 KIDNEY MODELS
- 6.3.1 2D KIDNEY MODELS
- 6.3.1.1 Fresh kidney cells
- 6.3.1.1.1 Accurate representation and functionality to support usage
- 6.3.1.2 Cryopreserved kidney cells
- 6.3.1.2.1 Long-term storage benefits to drive market
- 6.3.1.3 Other 2D kidney models
- 6.3.1.1 Fresh kidney cells
- 6.3.2 3D KIDNEY MODELS
- 6.3.2.1 Kidney organoids
- 6.3.2.1.1 Increasing incidence of chronic kidney disease to boost market growth
- 6.3.2.2 3D bioprinted kidney models
- 6.3.2.2.1 High cost of bioprinting to hinder market growth
- 6.3.2.3 Kidney spheroids
- 6.3.2.3.1 Feasibility of studying challenging kidney diseases to drive adoption
- 6.3.2.4 Other 3D kidney models
- 6.3.2.1 Kidney organoids
- 6.3.1 2D KIDNEY MODELS
- 6.4 PANCREATIC MODELS
- 6.4.1 2D PANCREATIC MODELS
- 6.4.1.1 Fresh pancreatic cells
- 6.4.1.1.1 High responsiveness to stimuli to support demand
- 6.4.1.2 Cryopreserved pancreatic cells
- 6.4.1.2.1 Potential use of cryopreserved cells in regenerative therapies and transplantation to increase demand
- 6.4.1.3 Other 2D pancreatic models
- 6.4.1.1 Fresh pancreatic cells
- 6.4.2 3D PANCREATIC MODELS
- 6.4.2.1 Pancreatic organoids
- 6.4.2.1.1 Increasing prevalence of diabetes and pancreatic cancer to drive uptake of pancreatic organoids
- 6.4.2.2 3D bioprinted pancreatic models
- 6.4.2.2.1 Precise fabrication and close resemblance to native architecture to drive adoption
- 6.4.2.3 Pancreatic spheroids
- 6.4.2.3.1 Improved methods for 3D cell culture to promote spheroid formation and support market growth
- 6.4.2.4 Other 3D pancreatic models
- 6.4.2.1 Pancreatic organoids
- 6.4.1 2D PANCREATIC MODELS
- 6.5 COLORECTAL MODELS
- 6.5.1 2D COLORECTAL MODELS
- 6.5.1.1 Fresh colorectal cells
- 6.5.1.1.1 Increasing incidence of colorectal cancer worldwide to heighten demand for fresh cells
- 6.5.1.2 Cryopreserved colorectal cells
- 6.5.1.2.1 Ability to thaw and culture cells on demand to support efficient research process, reducing need for continuous tissue sourcing
- 6.5.1.3 Other 2D colorectal models
- 6.5.1.1 Fresh colorectal cells
- 6.5.2 3D COLORECTAL MODELS
- 6.5.2.1 Colorectal organoids
- 6.5.2.1.1 Drive to enhance therapeutic interventions will support growth
- 6.5.2.2 3D bioprinted colorectal models
- 6.5.2.2.1 Increasing bioburden of colorectal cancer to drive market growth
- 6.5.2.3 Colorectal spheroids
- 6.5.2.3.1 Advantages in determining disease mechanisms and drug testing to drive adoption
- 6.5.2.4 Other 3D colorectal models
- 6.5.2.1 Colorectal organoids
- 6.5.1 2D COLORECTAL MODELS
- 6.6 HEART MODELS
- 6.6.1 2D HEART MODELS
- 6.6.1.1 Fresh heart cells
- 6.6.1.1.1 Importance in regenerative medicine applications to support adoption
- 6.6.1.2 Cryopreserved heart cells
- 6.6.1.2.1 On-demand access for clinical or research use to drive uptake of cryopreserved cells
- 6.6.1.3 Other 2D heart models
- 6.6.1.1 Fresh heart cells
- 6.6.2 3D HEART MODELS
- 6.6.2.1 Heart organoids
- 6.6.2.1.1 Rising demand in cardiogenesis research to propel market growth
- 6.6.2.2 3D bioprinted heart models
- 6.6.2.2.1 High production costs to hinder adoption
- 6.6.2.3 Heart spheroids
- 6.6.2.3.1 Challenges in controlling spheroid morphology to restrain growth
- 6.6.2.4 Other 3D heart models
- 6.6.2.1 Heart organoids
- 6.6.1 2D HEART MODELS
- 6.7 LUNG MODELS
- 6.7.1 2D LUNG MODELS
- 6.7.1.1 Fresh lung cells
- 6.7.1.1.1 Use of fresh lung cells gaining momentum due to their ability to accurately replicate native lung environment
- 6.7.1.2 Cryopreserved lung cells
- 6.7.1.2.1 Advancements in slicing and cryopreservation to enable creation of thousands of hPCLS from a single lung
- 6.7.1.3 Other 2D lung models
- 6.7.1.1 Fresh lung cells
- 6.7.2 3D LUNG MODELS
- 6.7.2.1 Lung organoids
- 6.7.2.1.1 Increased adoption in biological research areas to boost market growth
- 6.7.2.2 3D bioprinted lung models
- 6.7.2.2.1 Advancements in bioinks to support uptake of 3D bioprinted lung models
- 6.7.2.3 Lung spheroids
- 6.7.2.3.1 Advantages of physiologically relevant environments for evaluating drug efficacy and toxicity to support usage
- 6.7.2.4 Other 3D lung models
- 6.7.2.1 Lung organoids
- 6.7.1 2D LUNG MODELS
- 6.8 OTHER PRODUCTS
- 6.8.1 2D MODELS (OTHER PRODUCTS)
- 6.8.1.1 Fresh cells (other products)
- 6.8.1.1.1 New techniques for isolating and preserving fresh cells to help enhance quality of research
- 6.8.1.2 Cryopreserved cells (other products)
- 6.8.1.2.1 Long-term storage benefits and advancements in research to support adoption
- 6.8.1.3 Other 2D models
- 6.8.1.1 Fresh cells (other products)
- 6.8.2 3D MODELS (OTHER PRODUCTS)
- 6.8.2.1 Organoids (other products)
- 6.8.2.1.1 Growing focus on collaboration fosters innovation in organoid development
- 6.8.2.2 3D bioprinted models (other products)
- 6.8.2.2.1 Lack of suitable bioinks for 3D bioprinting applications to hamper market growth
- 6.8.2.3 Spheroids (other products)
- 6.8.2.3.1 Predictive environment for assessing efficacy and safety to support adoption
- 6.8.2.4 Other 3D models (other products)
- 6.8.2.1 Organoids (other products)
- 6.8.1 2D MODELS (OTHER PRODUCTS)
7 HUMAN ORGANOIDS MARKET, BY SOURCE
- 7.1 INTRODUCTION
- 7.2 ADULT STEM CELLS
- 7.2.1 ADULT STEM CELLS TO HOLD LARGEST SHARE OF MARKET, BY SOURCE
- 7.3 INDUCED PLURIPOTENT STEM CELLS
- 7.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE UPTAKE OF IPSCS
- 7.4 EMBRYONIC STEM CELLS
- 7.4.1 ETHICAL CONCERNS ASSOCIATED WITH ESCS TO HINDER MARKET GROWTH
- 7.5 OTHER SOURCES
8 HUMAN ORGANOIDS MARKET, BY TYPE
- 8.1 INTRODUCTION
- 8.2 READY-TO-USE PRODUCTS
- 8.2.1 MASS PRODUCTION OF READY-TO-USE PRODUCTS TO DRIVE ADOPTION
- 8.3 CUSTOMIZABLE PRODUCTS
- 8.3.1 ADVANCEMENTS IN 3D BIOPRINTING TO PROPEL MARKET GROWTH
9 HUMAN ORGANOIDS MARKET, BY CULTURE METHOD
- 9.1 INTRODUCTION
- 9.2 MATRIGEL MATRIX CULTURE
- 9.2.1 LONG-STANDING USE AND EFFECTIVENESS IN GROWING ORGANOIDS TO ENSURE ADOPTION
- 9.3 AIR-LIQUID INTERFACE CULTURE
- 9.3.1 INCREASING PREVALENCE OF DISEASES AFFECTING EPITHELIAL TISSUES TO DRIVE ADOPTION
- 9.4 SUSPENSION CULTURE
- 9.4.1 COST-EFFECTIVENESS OF SUSPENSION CULTURE TO DRIVE MARKET
- 9.5 3D BIOPRINTING CULTURE
- 9.5.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO BOOST MARKET GROWTH
- 9.6 OTHER CULTURE METHODS
10 HUMAN ORGANOIDS MARKET, BY DISEASE AREA
- 10.1 INTRODUCTION
- 10.2 ONCOLOGY
- 10.2.1 GROWING FOCUS ON PERSONALIZED MEDICINE IN ONCOLOGY TO DRIVE DEMAND FOR CANCER ORGANOIDS
- 10.3 LIVER DISEASES
- 10.3.1 INCREASING INCIDENCE OF LIVER-RELATED CONDITIONS TO DRIVE DEMAND FOR EFFECTIVE RESEARCH MODELS
- 10.4 GASTROINTESTINAL DISEASES
- 10.4.1 WIDE USAGE IN MODELING INFLAMMATORY BOWEL DISEASE AND MALIGNANCIES TO PROPEL MARKET
- 10.5 CARDIOVASCULAR DISEASES
- 10.5.1 RISING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
- 10.6 INFECTIOUS DISEASES
- 10.6.1 USE OF ORGANOIDS IN DEVELOPING ANTIVIRAL DRUGS TO SUPPORT MARKET GROWTH
- 10.7 NEUROLOGICAL DISORDERS
- 10.7.1 GROWING INCIDENCE OF NEUROPSYCHIATRIC DISORDERS TO FUEL UPTAKE OF HUMAN ORGANOIDS
- 10.8 OTHER DISEASE AREAS
11 HUMAN ORGANOIDS MARKET, BY APPLICATION
- 11.1 INTRODUCTION
- 11.2 DEVELOPMENTAL BIOLOGY
- 11.2.1 TECHNOLOGICAL ADVANCEMENTS IN STEM CELL RESEARCH TO BOOST MARKET GROWTH
- 11.3 DRUG TOXICITY & EFFICACY TESTING
- 11.3.1 INCREASED DRUG DEVELOPMENT COSTS TO DRIVE GROWTH
- 11.4 DISEASE PATHOLOGY
- 11.4.1 INCREASED DEMAND FOR ADVANCED IN VITRO DISEASE STUDIES TO AUGMENT MARKET GROWTH
- 11.5 PERSONALIZED MEDICINE
- 11.5.1 HIGH COST AND INSUFFICIENT DATA TO HAMPER MARKET GROWTH
- 11.6 REGENERATIVE MEDICINE
- 11.6.1 INCREASING FUNDING ACTIVITIES TO PROPEL MARKET GROWTH
- 11.7 OTHER APPLICATIONS
12 HUMAN ORGANOIDS MARKET, BY END USER
- 12.1 INTRODUCTION
- 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 12.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET GROWTH
- 12.3 CONTRACT RESEARCH ORGANIZATIONS
- 12.3.1 INCREASING OUTSOURCING OF CLINICAL RESEARCH SERVICES TO SUPPORT MARKET GROWTH
- 12.4 ACADEMIC & RESEARCH INSTITUTES
- 12.4.1 RISING GOVERNMENT FUNDING AND INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET
- 12.5 OTHER END USERS
13 HUMAN ORGANOIDS MARKET, BY REGION
- 13.1 INTRODUCTION
- 13.2 NORTH AMERICA
- 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 13.2.2 US
- 13.2.2.1 Rising prevalence of chronic respiratory diseases and organ transplants to expedite growth
- 13.2.3 CANADA
- 13.2.3.1 Growing incidence of cancer and investments in disease diagnostics & life science research to drive market
- 13.3 EUROPE
- 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 13.3.2 GERMANY
- 13.3.2.1 Higher healthcare spending and organ transplants to favor market growth
- 13.3.3 UK
- 13.3.3.1 Rising disease prevalence to drive market growth
- 13.3.4 FRANCE
- 13.3.4.1 Increasing availability of advanced medical technologies to support market growth
- 13.3.5 ITALY
- 13.3.5.1 Modernization of healthcare infrastructure to support market
- 13.3.6 SPAIN
- 13.3.6.1 Rising incidences of cancer to drive demand
- 13.3.7 REST OF EUROPE
- 13.4 ASIA PACIFIC
- 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 13.4.2 CHINA
- 13.4.2.1 Healthcare infrastructure improvements to support market growth in China
- 13.4.3 JAPAN
- 13.4.3.1 Rising biomedical & medical research to support market growth
- 13.4.4 INDIA
- 13.4.4.1 Large patient population and developing healthcare sector to drive market
- 13.4.5 AUSTRALIA
- 13.4.5.1 Rising private and public funding for research activities to drive market
- 13.4.6 SOUTH KOREA
- 13.4.6.1 Favorable government policies to fuel market growth
- 13.4.7 REST OF ASIA PACIFIC
- 13.5 LATIN AMERICA
- 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 13.5.2 BRAZIL
- 13.5.2.1 Growing pharmaceuticals market and budget allocations to boost market
- 13.5.3 MEXICO
- 13.5.3.1 Booming medical tourism to support growth
- 13.5.4 REST OF LATIN AMERICA
- 13.6 MIDDLE EAST & AFRICA
- 13.6.1 GROWING FOCUS ON IMPROVING QUALITY OF LIFE TO DRIVE MARKET
- 13.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 13.7 GCC COUNTRIES
- 13.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE TO AUGMENT MARKET
- 13.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
14 COMPETITIVE LANDSCAPE
- 14.1 INTRODUCTION
- 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HUMAN ORGANOIDS MARKET
- 14.3 REVENUE ANALYSIS, 2021-2023
- 14.4 MARKET SHARE ANALYSIS, 2023
- 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 14.5.1 STARS
- 14.5.2 EMERGING LEADERS
- 14.5.3 PERVASIVE PLAYERS
- 14.5.4 PARTICIPANTS
- 14.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
- 14.5.5.1 Company footprint
- 14.5.5.2 Region footprint
- 14.5.5.3 Product footprint
- 14.5.5.4 Source footprint
- 14.5.5.5 Application footprint
- 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 14.6.1 PROGRESSIVE COMPANIES
- 14.6.2 RESPONSIVE COMPANIES
- 14.6.3 DYNAMIC COMPANIES
- 14.6.4 STARTING BLOCKS
- 14.6.5 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023
- 14.7 COMPANY VALUATION AND FINANCIAL METRICS
- 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
- 14.8.1 BIOIVT
- 14.8.2 BECYTES BIOTECHNOLOGIES
- 14.9 COMPETITIVE SCENARIO
- 14.9.1 PRODUCT LAUNCHES
- 14.9.2 DEALS
15 COMPANY PROFILES
- 15.1 KEY PLAYERS
- 15.1.1 THERMO FISHER SCIENTIFIC INC.
- 15.1.1.1 Business overview
- 15.1.1.2 Products offered
- 15.1.1.3 Recent developments
- 15.1.1.3.1 Product launches
- 15.1.1.3.2 Deals
- 15.1.1.4 MnM view
- 15.1.1.4.1 Right to win
- 15.1.1.4.2 Strategic choices
- 15.1.1.4.3 Weaknesses and competitive threats
- 15.1.2 CORNING INCORPORATED
- 15.1.2.1 Business overview
- 15.1.2.2 Products offered
- 15.1.2.3 Recent developments
- 15.1.2.3.1 Deals
- 15.1.2.4 MnM view
- 15.1.2.4.1 Right to win
- 15.1.2.4.2 Strategic choices
- 15.1.2.4.3 Weaknesses and competitive threats
- 15.1.3 MERCK KGAA
- 15.1.3.1 Business overview
- 15.1.3.2 Products offered
- 15.1.3.3 Recent developments
- 15.1.3.3.1 Deals
- 15.1.3.3.2 Expansions
- 15.1.3.4 MnM view
- 15.1.3.4.1 Right to win
- 15.1.3.4.2 Strategic choices
- 15.1.3.4.3 Weaknesses and competitive threats
- 15.1.4 BIOIVT
- 15.1.4.1 Business overview
- 15.1.4.2 Products offered
- 15.1.4.3 Recent developments
- 15.1.4.3.1 Deals
- 15.1.4.4 MnM view
- 15.1.4.4.1 Right to win
- 15.1.4.4.2 Strategic choices
- 15.1.4.4.3 Weaknesses and competitive threats
- 15.1.5 HUB ORGANOIDS BV
- 15.1.5.1 Business overview
- 15.1.5.2 Products offered
- 15.1.5.3 Recent developments
- 15.1.5.3.1 Deals
- 15.1.5.4 MnM view
- 15.1.5.4.1 Right to win
- 15.1.5.4.2 Strategic choices
- 15.1.5.4.3 Weaknesses and competitive threats
- 15.1.6 BICO
- 15.1.6.1 Business overview
- 15.1.6.2 Products offered
- 15.1.6.3 Recent developments
- 15.1.6.3.1 Product launches
- 15.1.6.3.2 Deals
- 15.1.6.3.3 Other developments
- 15.1.7 BECYTES BIOTECHNOLOGIES
- 15.1.7.1 Business overview
- 15.1.7.2 Products offered
- 15.1.8 INSPHERO
- 15.1.8.1 Business overview
- 15.1.8.2 Products offered
- 15.1.8.3 Recent developments
- 15.1.8.3.1 Deals
- 15.1.9 GBA GROUP
- 15.1.9.1 Business overview
- 15.1.9.2 Products offered
- 15.1.9.3 Recent developments
- 15.1.9.3.1 Deals
- 15.1.10 KIRKSTALL LTD.
- 15.1.10.1 Business overview
- 15.1.10.2 Products offered
- 15.1.11 MIMETAS BV
- 15.1.11.1 Business overview
- 15.1.11.2 Products offered
- 15.1.11.3 Recent developments
- 15.1.11.3.1 Product launches
- 15.1.11.3.2 Deals
- 15.1.12 NEUROMICS
- 15.1.12.1 Business overview
- 15.1.12.2 Products offered
- 15.1.13 PRIMACYT CELL CULTURE TECHNOLOGY GMBH
- 15.1.13.1 Business overview
- 15.1.13.2 Products offered
- 15.1.14 STEMCELL TECHNOLOGIES
- 15.1.14.1 Business overview
- 15.1.14.2 Products offered
- 15.1.14.3 Recent developments
- 15.1.14.3.1 Expansions
- 15.1.1 THERMO FISHER SCIENTIFIC INC.
- 15.2 OTHER PLAYERS
- 15.2.1 ACROBIOSYSTEMS
- 15.2.2 BIOPREDIC INTERNATIONAL
- 15.2.3 CN BIO INNOVATIONS LTD.
- 15.2.4 CYPRIO
- 15.2.5 EMULATE, INC.
- 15.2.6 KERAFAST, INC.
- 15.2.7 PANDORUM TECHNOLOGIES PVT. LTD.
- 15.2.8 CYFUSE BIOMEDICAL KK
- 15.2.9 NEYROBLASTGX LLC
- 15.2.10 3DNAMICS INC.
- 15.2.11 DEFINIGEN LIMITED
16 APPENDIX
- 16.1 DISCUSSION GUIDE
- 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 16.3 CUSTOMIZATION OPTIONS
- 16.4 RELATED REPORTS
- 16.5 AUTHOR DETAILS
List of Tables
- TABLE 1 INVESTMENTS AND FUNDS FOR HUMAN ORGANOID RESEARCH
- TABLE 2 RESEARCH PROJECTS AND ACTIVITIES
- TABLE 3 AVERAGE SELLING PRICE OF HUMAN ORGANOID PRODUCTS, BY TYPE, 2022-2024
- TABLE 4 AVERAGE SELLING PRICE OF HUMAN ORGANOID PRODUCTS, BY REGION, 2022-2024
- TABLE 5 HUMAN ORGANOIDS MARKET: LIST OF MAJOR PATENTS, 2022-2023
- TABLE 6 IMPORT DATA FOR HS CODE 3002, WHICH INCLUDES CELL CULTURES, WHETHER OR NOT MODIFIED, 2019-2023 (USD MILLION)
- TABLE 7 EXPORT DATA FOR HS CODE 3002, WHICH INCLUDES CELL CULTURES, WHETHER OR NOT MODIFIED, BY COUNTRY, 2019-2023 (USD MILLION)
- TABLE 8 HUMAN ORGANOIDS MARKET: ROLE IN ECOSYSTEM
- TABLE 9 HUMAN ORGANOIDS MARKET: PORTER'S FIVE FORCES
- TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HUMAN ORGANOIDS (%)
- TABLE 11 KEY BUYING CRITERIA FOR HUMAN ORGANOIDS, BY TYPE
- TABLE 12 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 13 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 14 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 15 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 16 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 17 HUMAN ORGANOIDS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024-DECEMBER 2025
- TABLE 18 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 19 LIVER MODELS: KEY PRODUCTS OFFERED, BY COMPANY
- TABLE 20 LIVER AND INTRAHEPATIC BILE DUCT CANCER INCIDENCE, 2022
- TABLE 21 HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 22 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 23 EUROPE: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 24 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 25 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 26 HUMAN ORGANOIDS MARKET FOR LIVER MODELS, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 27 2D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 28 2D LIVER MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 29 FRESH HEPATOCYTES: KEY PRODUCTS OFFERED, BY COMPANY
- TABLE 30 FRESH HEPATOCYTES MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 31 CRYOPRESERVED HEPATOCYTES: KEY PRODUCTS OFFERED, BY COMPANY
- TABLE 32 CRYOPRESERVED HEPATOCYTES MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 33 OTHER 2D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 34 3D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 35 3D LIVER MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 36 LIVER ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 37 3D BIOPRINTED LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 38 LIVER SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 39 LIVER-ON-A CHIP MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 40 OTHER 3D LIVER MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 41 KIDNEY MODELS: KEY PRODUCTS OFFERED, BY COMPANY
- TABLE 42 KIDNEY CANCER INCIDENCE, 2022
- TABLE 43 HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 44 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 45 EUROPE: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 46 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 47 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 48 HUMAN ORGANOIDS MARKET FOR KIDNEY MODELS, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 49 2D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 50 2D KIDNEY MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 51 FRESH KIDNEY CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 52 CRYOPRESERVED KIDNEY CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 53 OTHER 2D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 54 3D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 55 3D KIDNEY MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 56 KIDNEY ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 57 3D BIOPRINTED KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 58 KIDNEY SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 59 OTHER 3D KIDNEY MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 60 PANCREATIC MODELS: KEY PRODUCTS OFFERED, BY COMPANY
- TABLE 61 PANCREATIC CANCER INCIDENCE, 2022
- TABLE 62 HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 63 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 64 EUROPE: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 65 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 66 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 67 HUMAN ORGANOIDS MARKET FOR PANCREATIC MODELS, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 68 2D PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 69 2D PANCREATIC MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 70 FRESH PANCREATIC CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 71 CRYOPRESERVED PANCREATIC CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 72 OTHER 2D PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 73 3D PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 74 3D PANCREATIC MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 75 PANCREATIC ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 76 3D BIOPRINTED PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 77 PANCREATIC SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 78 OTHER 3D PANCREATIC MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 79 COLORECTAL MODELS: KEY PRODUCTS OFFERED, BY COMPANY
- TABLE 80 COLORECTAL CANCER INCIDENCE, 2022
- TABLE 81 HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 82 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 83 EUROPE: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 84 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 85 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 86 HUMAN ORGANOIDS MARKET FOR COLORECTAL MODELS, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 87 2D COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 88 2D COLORECTAL MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 89 FRESH COLORECTAL CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 90 CRYOPRESERVED COLORECTAL CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 91 OTHER 2D COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 92 3D COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 93 3D COLORECTAL MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 94 COLORECTAL ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 95 3D BIOPRINTED COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 96 COLORECTAL SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 97 OTHER 3D COLORECTAL MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 98 HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 99 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 100 EUROPE: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 101 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 102 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 103 HUMAN ORGANOIDS MARKET FOR HEART MODELS, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 104 2D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 105 2D HEART MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 106 FRESH HEART CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 107 CRYOPRESERVED HEART CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 108 OTHER 2D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 109 3D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 110 3D HEART MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 111 HEART ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 112 3D BIOPRINTED HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 113 HEART SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 114 OTHER 3D HEART MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 115 LUNG MODELS: KEY PRODUCTS OFFERED, BY COMPANY
- TABLE 116 LUNG CANCER INCIDENCE,2022
- TABLE 117 HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 118 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 119 EUROPE: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 120 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 121 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 122 HUMAN ORGANOIDS MARKET FOR LUNG MODELS, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 123 2D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 124 2D LUNG MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 125 FRESH LUNG CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 126 CRYOPRESERVED LUNG CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 127 OTHER 2D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 128 3D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 129 3D LUNG MODELS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 130 LUNG ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 131 3D BIOPRINTED LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 132 LUNG SPHEROIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 133 OTHER 3D LUNG MODELS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 134 OTHER PRODUCTS: KEY PRODUCTS OFFERED, BY COMPANY
- TABLE 135 BRAIN, CENTRAL NERVOUS SYSTEM, AND BREAST CANCER INCIDENCE, 2022
- TABLE 136 OTHER HUMAN ORGANOID PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 137 NORTH AMERICA: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 138 EUROPE: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 139 ASIA PACIFIC: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 140 LATIN AMERICA: OTHER HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 141 OTHER HUMAN ORGANOID PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 142 2D MODELS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 143 2D MODELS (OTHER PRODUCTS) MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 144 FRESH CELLS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 145 CRYOPRESERVED CELLS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 146 OTHER 2D MODELS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 147 3D MODELS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 148 3D MODELS (OTHER PRODUCTS) MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 149 ORGANOIDS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 150 3D BIOPRINTED MODELS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 151 SPHEROIDS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 152 OTHER 3D MODELS (OTHER PRODUCTS) MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 153 HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 154 ADULT STEM CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 155 NORTH AMERICA: ADULT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 156 EUROPE: ADULT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 157 ASIA PACIFIC: ADULT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 158 LATIN AMERICA: ADULT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 159 INDUCED PLURIPOTENT STEM CELLS: KEY PRODUCTS OFFERED, BY COMPANY
- TABLE 160 INDUCED PLURIPOTENT STEM CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 161 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 162 EUROPE: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 163 ASIA PACIFIC: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 164 LATIN AMERICA: INDUCED PLURIPOTENT STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 165 EMBRYONIC STEM CELLS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 166 NORTH AMERICA: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 167 EUROPE: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 168 ASIA PACIFIC: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 169 LATIN AMERICA: EMBRYONIC STEM CELLS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 170 OTHER SOURCES: KEY PRODUCTS OFFERED, BY COMPANY
- TABLE 171 OTHER HUMAN ORGANOID SOURCES MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 172 NORTH AMERICA: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 173 EUROPE: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 174 ASIA PACIFIC: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 175 LATIN AMERICA: OTHER HUMAN ORGANOID SOURCES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 176 HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 177 READY-TO-USE PRODUCTS MARKET: KEY PRODUCTS, BY COMPANY
- TABLE 178 READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 179 NORTH AMERICA: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 180 EUROPE: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 181 ASIA PACIFIC: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 182 LATIN AMERICA: READY-TO-USE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 183 CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 184 NORTH AMERICA: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 185 EUROPE: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 186 ASIA PACIFIC: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 187 LATIN AMERICA: CUSTOMIZABLE HUMAN ORGANOID PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 188 HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 189 HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY REGION, 2022-2029 (USD MILLION)
- TABLE 190 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 191 EUROPE: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 192 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 193 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR MATRIGEL MATRIX CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 194 HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY REGION, 2022-2029 (USD MILLION)
- TABLE 195 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 196 EUROPE: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 197 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 198 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR AIR-LIQUID INTERFACE CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 199 HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY REGION, 2022-2029 (USD MILLION)
- TABLE 200 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 201 EUROPE: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 202 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 203 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR SUSPENSION CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 204 HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY REGION, 2022-2029 (USD MILLION)
- TABLE 205 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 206 EUROPE: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 207 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 208 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR 3D BIOPRINTING CULTURE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 209 HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 210 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 211 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 212 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 213 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER CULTURE METHODS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 214 HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 215 INCIDENCE OF CANCER CASES WORLDWIDE, IN 2022 VS 2045, BY CANCER TYPE
- TABLE 216 HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD MILLION)
- TABLE 217 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 218 EUROPE: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 219 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 220 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 221 HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY REGION, 2022-2029 (USD MILLION)
- TABLE 222 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 223 EUROPE: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 224 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 225 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR LIVER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 226 HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022-2029 (USD MILLION)
- TABLE 227 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 228 EUROPE: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 229 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 230 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 231 HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION)
- TABLE 232 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 233 EUROPE: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 234 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 235 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 236 HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES BY REGION, 2022-2029 (USD MILLION)
- TABLE 237 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 238 EUROPE: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 239 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 240 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 241 HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 242 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 243 EUROPE: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 244 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 245 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 246 HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 247 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 248 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 249 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 250 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 251 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 252 HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2022-2029 (USD MILLION)
- TABLE 253 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 254 EUROPE: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 255 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 256 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 257 HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY REGION, 2022-2029 (USD MILLION)
- TABLE 258 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 259 EUROPE: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 260 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 261 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DRUG TOXICITY & EFFICACY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 262 HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY REGION, 2022-2029 (USD MILLION)
- TABLE 263 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 264 EUROPE: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 265 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 266 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR DISEASE PATHOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 267 HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2022-2029 (USD MILLION)
- TABLE 268 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 269 EUROPE: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 270 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 271 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 272 HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY REGION, 2022-2029 (USD MILLION)
- TABLE 273 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 274 EUROPE: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 275 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 276 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 277 HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 278 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 279 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 280 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 281 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 282 HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 283 HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
- TABLE 284 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 285 EUROPE: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 286 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 287 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 288 HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 289 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 290 EUROPE: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 291 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 292 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 293 HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
- TABLE 294 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 295 EUROPE: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 296 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 297 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 298 HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
- TABLE 299 NORTH AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 300 EUROPE: HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 301 ASIA PACIFIC: HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 302 LATIN AMERICA: HUMAN ORGANOIDS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 303 HUMAN ORGANOIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
- TABLE 304 NORTH AMERICA: ESTIMATED NUMBER OF NEW CANCER CASES FROM 0 TO 85+ YEARS OF AGE, 2022-2045
- TABLE 305 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 306 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 307 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 308 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 309 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 310 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 311 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 312 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 313 US: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 314 US: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 315 US: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 316 US: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 317 US: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 318 US: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 319 US: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 320 US: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 321 ESTIMATED PREVALENCE OF DIABETES IN CANADA, 2022 VS. 2023
- TABLE 322 CANADA: FIVE MOST-REPORTED CAUSES OF CANCER-RELATED MORTALITY, 2024
- TABLE 323 CANADA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 324 CANADA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 325 CANADA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 326 CANADA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 327 CANADA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 328 CANADA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 329 CANADA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 330 EUROPE: ESTIMATED NUMBER OF NEW CANCER CASES FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+]
- TABLE 331 EUROPE: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 332 EUROPE: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 333 EUROPE: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 334 EUROPE: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 335 EUROPE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 336 EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 337 EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 338 EUROPE: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 339 GERMANY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 340 GERMANY: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 341 GERMANY: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 342 GERMANY: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 343 GERMANY: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 344 GERMANY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 345 GERMANY: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 346 GERMANY: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 347 UK: INCIDENCE AND MORTALITY RATE OF HEART AND CIRCULATORY DISEASES (CVD), 2024
- TABLE 348 UK: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 349 UK: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 350 UK: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 351 UK: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 352 UK: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 353 UK: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 354 UK: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 355 UK: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 356 FRANCE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 357 FRANCE: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 358 FRANCE: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 359 FRANCE: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 360 FRANCE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 361 FRANCE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 362 FRANCE: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 363 FRANCE: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 364 ITALY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 365 ITALY: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 366 ITALY: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 367 ITALY: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 368 ITALY: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 369 ITALY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 370 ITALY: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 371 ITALY: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 372 SPAIN: CANCER INCIDENCE, 2022 VS 2023
- TABLE 373 SPAIN: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 374 SPAIN: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 375 SPAIN: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 376 SPAIN: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 377 SPAIN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 378 SPAIN: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 379 SPAIN: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 380 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 381 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 382 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 383 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 384 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 385 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 386 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 387 ASIA PACIFIC: ESTIMATED NUMBER OF NEW CANCER CASES FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+]
- TABLE 388 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 389 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 390 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 391 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 392 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 393 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 394 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 395 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 396 CHINA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 397 CHINA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 398 CHINA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 399 CHINA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 400 CHINA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 401 CHINA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 402 CHINA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 403 CHINA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 404 JAPAN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 405 JAPAN: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 406 JAPAN: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 407 JAPAN: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 408 JAPAN: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 409 JAPAN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 410 JAPAN: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 411 JAPAN: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 412 INDIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 413 INDIA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 414 INDIA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 415 INDIA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 416 INDIA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 417 INDIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 418 INDIA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 419 INDIA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 420 AUSTRALIA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 421 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 422 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 423 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 424 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 425 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 426 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 427 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 428 SOUTH KOREA: CANCER INCIDENCE, MORTALITY AND PREVALENCE, BY TYPE, 2022
- TABLE 429 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 430 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 431 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 432 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 433 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 434 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 435 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 436 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 437 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 438 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 439 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 440 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 441 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 442 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 443 LATIN AMERICA: ESTIMATED NUMBER OF CANCER NEW CASES FROM 2022 TO 2045, BOTH SEXES, AGE [0-85+]
- TABLE 444 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
- TABLE 445 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 446 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 447 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 448 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 449 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 450 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 451 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 452 BRAZIL: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 453 BRAZIL: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 454 BRAZIL: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 455 BRAZIL: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 456 BRAZIL: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 457 BRAZIL: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 458 BRAZIL: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 459 BRAZIL: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 460 MEXICO: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY TYPE, 2022
- TABLE 461 MEXICO: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 462 MEXICO: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 463 MEXICO: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 464 MEXICO: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 465 MEXICO: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 466 MEXICO: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 467 MEXICO: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 468 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 469 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 470 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 471 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 472 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 473 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 474 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 475 AFRICA: ESTIMATED NUMBER OF NEW CANCER CASES BETWEEN 0 TO 85+ OF AGE, 2022-2045
- TABLE 476 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 477 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 478 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 479 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 480 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 481 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 482 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 483 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
- TABLE 484 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
- TABLE 485 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY TYPE, 2022-2029 (USD MILLION)
- TABLE 486 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2022-2029 (USD MILLION)
- TABLE 487 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
- TABLE 488 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
- TABLE 489 GCC COUNTRIES: HUMAN ORGANOIDS MARKET, BY END USER, 2022-2029 (USD MILLION)
- TABLE 490 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN HUMAN ORGANOIDS MARKET
- TABLE 491 HUMAN ORGANOIDS MARKET: DEGREE OF COMPETITION
- TABLE 492 HUMAN ORGANOIDS MARKET: REGION FOOTPRINT
- TABLE 493 HUMAN ORGANOIDS MARKET: PRODUCT FOOTPRINT
- TABLE 494 HUMAN ORGANOIDS MARKET: SOURCE FOOTPRINT
- TABLE 495 HUMAN ORGANOIDS MARKET: APPLICATION FOOTPRINT
- TABLE 496 HUMAN ORGANOIDS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
- TABLE 497 HUMAN ORGANOIDS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
- TABLE 498 HUMAN ORGANOIDS MARKET: PRODUCT LAUNCHES, JANUARY 2021- AUGUST 2024
- TABLE 499 HUMAN ORGANOIDS MARKET: DEALS, JANUARY 2021-AUGUST 2024
- TABLE 500 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
- TABLE 501 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED
- TABLE 502 THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
- TABLE 503 THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021-AUGUST 2024
- TABLE 504 CORNING INCORPORATED: COMPANY OVERVIEW
- TABLE 505 CORNING INCORPORATED: PRODUCTS OFFERED
- TABLE 506 CORNING INCORPORATED: DEALS, JANUARY 2021-AUGUST 2024
- TABLE 507 MERCK: COMPANY OVERVIEW
- TABLE 508 MERCK: PRODUCTS OFFERED
- TABLE 509 MERCK: DEALS, JANUARY 2021-AUGUST 2024
- TABLE 510 MERCK: EXPANSIONS, JANUARY 2021-AUGUST 2024
- TABLE 511 BIOIVT: COMPANY OVERVIEW
- TABLE 512 BIOIVT: PRODUCTS OFFERED
- TABLE 513 BIOIVT: DEALS, JANUARY 2021-AUGUST 2024
- TABLE 514 HUB ORGANOIDS: COMPANY OVERVIEW
- TABLE 515 HUB ORGANOIDS: PRODUCTS OFFERED
- TABLE 516 HUB ORGANOIDS: DEALS, JANUARY 2021-AUGUST 2024
- TABLE 517 BICO: COMPANY OVERVIEW
- TABLE 518 BICO: PRODUCTS OFFERED
- TABLE 519 BICO: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
- TABLE 520 BICO: DEALS, JANUARY 2021-JUNE 2024
- TABLE 521 BICO: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
- TABLE 522 BECYTES BIOTECHNOLOGIES: COMPANY OVERVIEW
- TABLE 523 BECYTES BIOTECHNOLOGIES: PRODUCTS OFFERED
- TABLE 524 INSPHERO: COMPANY OVERVIEW
- TABLE 525 INSPHERO: PRODUCTS OFFERED
- TABLE 526 INSPHERO: DEALS, JANUARY 2021-AUGUST 2024
- TABLE 527 GBA GROUP: COMPANY OVERVIEW
- TABLE 528 GBA GROUP: PRODUCTS OFFERED
- TABLE 529 GBA GROUP: DEALS, JANUARY 2021-AUGUST 2024
- TABLE 530 KIRKSTALL: COMPANY OVERVIEW
- TABLE 531 KIRKSTALL: PRODUCTS OFFERED
- TABLE 532 MIMETAS: COMPANY OVERVIEW
- TABLE 533 MIMETAS: PRODUCTS OFFERED
- TABLE 534 MIMETAS: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
- TABLE 535 MIMETAS: DEALS, JANUARY 2021-AUGUST 2024
- TABLE 536 NEUROMICS: COMPANY OVERVIEW
- TABLE 537 NEUROMICS: PRODUCTS OFFERED
- TABLE 538 PRIMACYT CELL CULTURE TECHNOLOGY GMBH: COMPANY OVERVIEW
- TABLE 539 PRIMACYT CELL CULTURE TECHNOLOGY GMBH: PRODUCTS OFFERED
- TABLE 540 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW
- TABLE 541 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED
- TABLE 542 STEMCELL TECHNOLOGIES: DEALS, JANUARY 2021-AUGUST 2024
- TABLE 543 STEMCELL TECHNOLOGIES: EXPANSIONS, JANUARY 2021-AUGUST 2024
List of Figures
- FIGURE 1 HUMAN ORGANOIDS MARKET: RESEARCH DESIGN METHODOLOGY
- FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
- FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
- FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
- FIGURE 6 HUMAN ORGANOIDS MARKET: TOP-DOWN APPROACH
- FIGURE 7 DATA TRIANGULATION METHODOLOGY
- FIGURE 8 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
- FIGURE 9 HUMAN ORGANOIDS MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
- FIGURE 10 HUMAN ORGANOIDS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
- FIGURE 11 HUMAN ORGANOIDS MARKET, BY CULTURE METHOD, 2024 VS. 2029 (USD MILLION)
- FIGURE 12 HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2024 VS. 2029 (USD MILLION)
- FIGURE 13 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
- FIGURE 14 HUMAN ORGANOIDS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
- FIGURE 15 HUMAN ORGANOIDS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
- FIGURE 16 GROWING FOCUS ON DEVELOPING ALTERNATIVES FOR ANIMAL TESTING MODELS TO DRIVE MARKET GROWTH
- FIGURE 17 LIVER MODELS TO DOMINATE MARKET TILL 2029
- FIGURE 18 ADULT STEM CELLS SEGMENT TO HOLD LARGEST SHARE TILL 2029
- FIGURE 19 READY-TO-USE PRODUCTS SEGMENT TO RETAIN MARKET LEADERSHIP
- FIGURE 20 DEVELOPMENTAL BIOLOGY AND DRUG TOXICITY & EFFICACY TESTING TO COMMAND LARGEST SHARES
- FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET IN 2029
- FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
- FIGURE 23 HUMAN ORGANOIDS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 24 NUMBER OF CLINICAL TRIALS, BY COUNTRY, 2022
- FIGURE 25 NUMBER OF ARTICLES RELATED TO HUMAN ORGANOIDS, 2018-2023
- FIGURE 26 US: NUMBER OF ORGAN TRANSPLANTS (2024)
- FIGURE 27 AVERAGE SELLING PRICE OF FRESH CELLS (2024)
- FIGURE 28 PATENT ANALYSIS FOR HUMAN ORGANOIDS (JANUARY 2014-DECEMBER 2023)
- FIGURE 29 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
- FIGURE 30 HUMAN ORGANOIDS MARKET: SUPPLY CHAIN ANALYSIS
- FIGURE 31 HUMAN ORGANOIDS MARKET: ECOSYSTEM ANALYSIS
- FIGURE 32 HUMAN ORGANOIDS MARKET: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF HUMAN ORGANOIDS
- FIGURE 34 KEY BUYING CRITERIA FOR HUMAN ORGANOIDS
- FIGURE 35 HUMAN ORGANOIDS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
- FIGURE 36 HUMAN ORGANOIDS MARKET: DEALS AND FUNDING
- FIGURE 37 MARKET POTENTIAL OF AI TO ENHANCE RESEARCH AND DEVELOPMENT IN HUMAN ORGANOIDS MARKET
- FIGURE 38 NORTH AMERICA: HUMAN ORGANOIDS MARKET SNAPSHOT
- FIGURE 39 ASIA PACIFIC: HUMAN ORGANOIDS MARKET SNAPSHOT
- FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET (2021-2023)
- FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET (2023)
- FIGURE 42 HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
- FIGURE 43 HUMAN ORGANOIDS MARKET: COMPANY FOOTPRINT
- FIGURE 44 HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
- FIGURE 45 EV/EBITDA OF KEY VENDORS
- FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 47 HUMAN ORGANOIDS MARKET: BRAND COMPARISON FOR HEPATOCYTES
- FIGURE 48 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
- FIGURE 49 CORNING INCORPORATED: COMPANY SNAPSHOT
- FIGURE 50 MERCK: COMPANY SNAPSHOT
- FIGURE 51 BICO: COMPANY SNAPSHOT
